We investigated the antimicrobial resistance in gonococci 2009 to 2014 in Yaoundé, Cameroon, and recommend revisions of the Cameroonian treatment guideline. We observed a high resistance to ciprofloxacin (17.6%) but no ceftriaxone resistance. Ceftriaxone should replace ciprofloxacin as the recommended first-line treatment for urethral/vaginal discharge. Enhanced resistance surveillance in Africa is essential.
The gonococcal resistance to first-line treatment for urethral/vaginal discharge, ciprofloxacin, in Cameroon increased from 3.8% to 50.0% during 2009 to 2014. Strengthening of the gonococcal antimicrobial resistance surveillance in Africa is essential.
From the *Catholic University of Central Africa, Yaoundé, Cameroon;
†Medical Bacteriology Laboratory, Centre Pasteur of Cameroon, Yaoundé, Cameroon; and
‡WHO Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory Medicine, Örebro University, Örebro, Sweden
Acknowledgements: The authors are very grateful to Dr. Ariane Nzouankeu and Dr. Marie C. Fonkoua for extensive support during the whole project. The authors are also grateful to the Heads and staff of Centre Pasteur of Cameroon and particularly the staff of the Medical Bacteriology Laboratory. The authors, finally, would like to thank the Heads and staff of the hospitals and health centers in Yaoundé for providing N. gonorrhoeae isolates and for other support in this study.
Conflicts of Interest: None declared.
Sources of Funding: Supported by funds from the Centre Pasteur of Cameroon, Yaoundé, Cameroon and the Department of Reproductive Health and Research, World Health Organization, Geneva.
Correspondence: Magnus Unemo, PhD, WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, SE-701 85 Örebro, Sweden. E-mail: firstname.lastname@example.org.
Received for publication April 28, 2018, and accepted July 17, 2018.